[{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Data from Octapharma's NuProtect Study Published in Immunogenicity of Nuwiq in Previously Untreated Critical Haemophilia A Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"H\u00e4mophilie-Zentrum Rhein Main","sponsor":"Octapharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MOTIVATE (MOdern Treatment of Inhibitor-Positive Patients with Haemophilia A) Enrolls First Patient in the US","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma to Present Its Continued Dedication to Improving Lives of People with Hemophilia and Von Willebrand Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Peptide","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Simoctocog Alfa
NUWIQ is a recombinant antihemophilic factor [coagulation factor VIII] indicated in adults and children with Hemophilia A for treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.
MOTIVATE trial comprised regimens of human cell line-derived recombinant FVIII Nuwiq® or the plasma-derived FVIII products octanate® or wilate® for the management of patients with hemophilia A and inhibitors.
The NuProtect study was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq®.